A recently launched Phase 1 clinical trial is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to ...

“This is an important step in the translation of iPSC-derived technology to clinical cell transplants in Parkinson’s,” Patrik Brundin, a neuroscientist at the Van Andel Institute in Michigan who did ...

iPSC-based therapies could replace, for example, the neurons that die off in Parkinson’s disease or the retinal tissue damaged by macular degeneration. Or perhaps they could obviate the need for ...

Patients' own stem cells to replace damaged dopamine cells in Parkinson’s disease, offering new hope. Parkinson's disease - ...

We have a long-standing interest in modeling Parkinson’s disease (PD) using human iPSC and ESC-derived dopamine neurons. “Induced aging” is a novel strategy to model late-onset features of diseases ...

Figure 3. Cerebral organoids as models for (A) Parkinson’s disease and (B) AAV capsid screening. Image Credit: ACROBiosystems Human iPSC-derived cardiac organoids were generated using Cardiac ...

A recently launched Phase 1 clinical trial at Mass General Brigham is examining the safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem ...

The in vitro modeling of human disease via iPSC-technology has proven successful for numerous developmental and early-onset disorders. However, recreating the pathogenesis of age-dependent conditions ...

Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated ...

Biotin supplementation reversed neurotoxicity in flies and iPSC-derived neurons ... aligns with a growing scientific recognition that Parkinson's is a multisystem disorder, with early symptoms ...

RNDP-001 has shown superior cell survival, innervation and behavioral rescue in preclinical models of Parkinson’s disease ... induced pluripotent stem cell (iPSC) technology, a Nobel Prize ...

The Phase 1 open-label clinical trial will be the first such trial to test blood-derived autologous iPSC-derived dopamine neurons in patients with Parkinson’s disease and is funded by the ...